Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Publications


Safi S, Krzykalla J, Hoffmann H, Benner A, Bischoff H, Eichhorn M, Kriegsmann M, Poschke I, Stögbauer F, Umansky L, Mogler C, Weichert W, Winter H, Beckhove P, Muley T.

Low tumor interleukin-1β expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: An identification and validation study.

Pulmonology. 2024 Apr 12

https://pubmed.ncbi.nlm.nih.gov/38614857/

Tan CL, Lindner K, Boschert T, Meng Z, Rodriguez Ehrenfried A, De Roia A, Haltenhof G, Faenza A, Imperatore F, Bunse L, Lindner JM, Harbottle RP, Ratliff M, Offringa R, Poschke I, Platten M, Green EW.

Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy.

Nat Biotechnol. 2024 Mar 7

https://pubmed.ncbi.nlm.nih.gov/38454173/

Boschert T, Kromer K, Lerner T, Lindner K, Haltenhof G, Tan CL, Jähne K, Poschke I, Bunse L, Eisele P, Grassl N, Mildenberger I, Sahm K, Platten M, Lindner JM, Green EW.

H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient.

Sci Adv, 2924 Feb 2

https://pubmed.ncbi.nlm.nih.gov/38306431/


Meyer M, Parpoulas C, Barthélémy T, Becker JP, Charoentong P, Lyu Y, Börsig S, Bulbuc N, Tessmer C, Weinacht L, Ibberson D, Schmidt P, Pipkorn R, Eichmüller SB, Steinberger P, Lindner K, Poschke I, Platten M, Fröhling S, Riemer AB, Hassel JC, Roberti MP, Jäger D, Zörnig I, Momburg F.

MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection.

Front Immunol. 2024 Jan 4

https://pubmed.ncbi.nlm.nih.gov/38239352/


Grassl N, Sahm K, Süße H, Poschke I, Bunse L, Bunse T, Boschert T, Mildenberger I, Rupp AK, Ewinger MP, Lanz LM, Denk M, Tabatabai G, Ronellenfitsch MW, Herrlinger U, Glas M, Krex D, Vajkoczy P, Wick A, Harting I, Sahm F, von Deimling A, Bendszus M, Wick W, Platten M.

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.

Neurol Res Pract. 2023 Oct 19

https://pubmed.ncbi.nlm.nih.gov/37853454/


Grassl N, Poschke I, Lindner K, Bunse L, Mildenberger I, Boschert T, Jähne K, Green EW, Hülsmeyer I, Jünger S, Kessler T, Suwala AK, Eisele P, Breckwoldt MO, Vajkoczy P, Grauer OM, Herrlinger U, Tonn JC, Denk M, Sahm F, Bendszus M, von Deimling A, Winkler F, Wick W, Platten M, Sahm K.

A H3K27M-targeted vaccine in adults with diffuse midline glioma.

Nat Med. 2023 Oct;29

https://pubmed.ncbi.nlm.nih.gov/37735561/

Lu KH, Michel J, Kilian M, Aslan K, Qi H, Kehl N, Jung S, Sanghvi K, Lindner K, Zhang XW, Green EW, Poschke I, Ratliff M, Bunse T, Sahm F, von Deimling A, Wick W, Platten M, Bunse L.

T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells.

Neurooncol Adv. 2022 Aug 31

https://pubmed.ncbi.nlm.nih.gov/36196364/

Liebers N, Speer C, Benning L, Bruch PM, Krämer I, Meissner J, Schnitzler P, Kräusslich HG, Dreger P, Müller-Tidow C, Poschke I, Dietrich S.

Humoral and cellular responses after COVID-19 vaccination in anti-CD20 treated lymphoma patients.

Blood. 2021 published online 10/2021

https://pubmed.ncbi.nlm.nih.gov/34669919/

Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, Green E, Justesen S, Behrens GA, Breckwoldt MO, Freitag A, Rother LM, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Stevanovic S, Tabatabai G, Steinbach JP, Bendszus M, von Deimling A, Schmitt M, Wick W.

A vaccine targeting mutant IDH1 in newly diagnosed glioma.

Nature. 2021 Apr;592(7854):463-468.

https://pubmed.ncbi.nlm.nih.gov/33762734/

 

Bunse L, Rupp AK, Poschke I, Bunse T, Lindner K, Wick A, Blobner J, Misch M, Tabatabai G, Glas M, Schnell O, Gempt J, Denk M, Reifenberger G, Bendszus M, Wuchter P, Steinbach JP, Wick W, Platten M.

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.

Neurol Res Pract. 2022 May 23 ; https://pubmed.ncbi.nlm.nih.gov/35599302/

van Tilburg CM, Witt R, Heiss M, Pajtler KW, Plass C, Poschke I, Platten M, Harting I, Sedlaczek O, Freitag A, Meyrath D, Taylor L, Balasubramanian GP, Jäger N, Pfaff E, Jones BC, Milde T, Pfister SM, Jones DTW, Kopp-Schneider A, Witt O.

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies.

BMC Cancer. 2020 Jun 5;20(1):523.

https://pubmed.ncbi.nlm.nih.gov/32503469/

 

Poschke IC, Hassel JC, Rodriguez-Ehrenfried A, Lindner KAM, Heras-Murillo I, Appel LM, Lehmann J, Lövgren T, Wickström SL, Lauenstein C, Roth J, König AK, Haanen JBAG, van den Berg J, Kiessling R, Bergmann F, Flossdorf M, Strobel O, Offringa R.

The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones.

Clin Cancer Res. 2020 Aug 15;26(16):4289-4301. Epub 2020 Apr 17.

https://pubmed.ncbi.nlm.nih.gov/32303540/

 

Buhl JL, Selt F, Hielscher T, Guiho R, Ecker J, Sahm F, Ridinger J, Riehl D, Usta D, Ismer B, Sommerkamp AC, Martinez-Barbera JP, Wefers AK, Remke M, Picard D, Pusch S, Gronych J, Oehme I, van Tilburg CM, Kool M, Kuhn D, Capper D, von Deimling A, Schuhmann MU, Herold-Mende C, Korshunov A, Brummer T, Pfister SM, Jones DTW, Witt O, Milde T.
 
The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma.

Clin Cancer Res. 2019 Mar 15;25(6):1851-1866.

https://www.ncbi.nlm.nih.gov/pubmed/30530705

 

Safi S, Yamauchi Y, Stamova S, Rathinasamy A, Op den Winkel J, Jünger S, Bucur M, Umansky L, Warth A, Herpel E, Eichhorn M, Winter H, Hoffmann H, Beckhove P.
 
Bone marrow expands the repertoire of functional T cells targeting tumor-associated antigens in patients with resectable non-small-cell lung cancer.

Oncoimmunology. 2019 Oct 23;8(12):e1671762.

https://www.ncbi.nlm.nih.gov/pubmed/31741774

 

Ge Y, Böhm HH, Rathinasamy A, Xydia M, Hu X, Pincha M, Umansky L, Breyer C, Hillier M, Bonertz A, Sevko A, Domschke C, Schuetz F, Frebel H, Dettling S, Herold-Mende C, Reissfelder C, Weitz J, Umansky V, Beckhove P
 
Tumor-Specific Regulatory T Cells from the Bone Marrow Orchestrate Antitumor Immunity in Breast Cancer.

Cancer Immunol Res. 2019 Dec;7(12):1998-2012

https://www.ncbi.nlm.nih.gov/pubmed/31672785

 

Bunse L, Green EW, Platten M.
 
High-throughput discovery of cancer-targeting TCRs.

Methods Enzymol. 2019;629:401-417.

https://www.ncbi.nlm.nih.gov/pubmed/31727251

 

Green EW, Bunse L, Bozza M, Sanghvi K, Platten M.
 
TCR validation toward gene therapy for cancer.

Methods Enzymol. 2019;629:419-441.

https://www.ncbi.nlm.nih.gov/pubmed/31727252

 

Lanz TV, Pröbstel AK, Mildenberger I, Platten M, Schirmer L.
 
Single-Cell High-Throughput Technologies in Cerebrospinal Fluid Research and Diagnostics.

Front Immunol. 2019 Jun 11;10:1302

https://www.ncbi.nlm.nih.gov/pubmed/31244848

 

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.
 
Actively personalized vaccination trial for newly diagnosed glioblastoma.

Nature. 2019 Jan;565(7738):240-245.Erratum in: Nature. 2019 Feb;566(7745):E13.

https://www.ncbi.nlm.nih.gov/pubmed/30568303

 

Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M.

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.

Nat Med. 2018 Aug;24(8):1192-1203

https://www.ncbi.nlm.nih.gov/pubmed/29988124

Platten M, Schilling D, Bunse L, Wick A, Bunse T, Riehl D, Karapanagiotou-Schenkel I, Harting I, Sahm F, Schmitt A, Steinbach J, Weyerbrock A, Hense J, Misch M, Krex D, Stevanović S, Tabatabai G, von Deimling A, Schmitt M, Wick W (2018).

A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).

Oral presentation at the Annual ASCO Conference 2018

https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2001

Buhl JL, Selt F, Hielscher T, Guiho R, Ecker J, Sahm F, Ridinger J, Riehl D, Usta D, Ismer B, Sommerkamp AC, Martinez-Babera JP, Wefers AK, Remke M, Picard D, Pusch S, Gronych J, Oehme I, van Tilburg CM, Kool M, Kuhn D, Capper D, von Deimling A, Schuhmann M, Herold-Mende C, Korshunov A, Brummer T, Pfister SM, Jones DTW, Witt O, Milde T.

The senescence-associated secretory phenotype mediates oncogene-induced senescence in pediatric pilocytic astrocytoma.

Clin Cancer Res. 2018 Dec 7.

https://www.ncbi.nlm.nih.gov/pubmed/30530705

Wabnitz GH, Kirchgessner H, Jahraus B, Umansky L, Shenolikar S, Samstag Y.

Protein Phosphatase 1αand Cofilin Regulate Nuclear Translocation of NF-κB and Promote Expression of the Anti-Inflammatory Cytokine Interleukin-10 by T Cells.

Mol Cell Biol. 2018 Oct 29;38(22).

https://www.ncbi.nlm.nih.gov/pubmed/30181394

Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Juenger S, Warth A, Eichhorn M, Muley T, Herth FJF, Dienemann H, Platten M, Beckhove P, Utikal J, Hoffmann H, Umansky V.

Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):777-787

https://www.ncbi.nlm.nih.gov/pubmed/29617574

Platten M, Bunse L, Riehl D, Bunse T, Ochs K, Wick W.

Vaccine Strategies in Gliomas.

Curr Treat Options Neurol. 2018 Mar 28;20(5):11.

https://www.ncbi.nlm.nih.gov/pubmed/29594595

Haag GM, Zoernig I, Hassel JC, Halama N, Dick J, Lang N, Podola L, Funk J, Ziegelmeier C, Juenger S, Bucur M, Umansky L, Falk CS, Freitag A, Karapanagiotou-Schenkel I, Beckhove P, Enk A, Jaeger D.

Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1. Eur J Cancer. 2018 Feb;90:122-129

https://www.ncbi.nlm.nih.gov/pubmed/29306769

Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P.

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.

Oncoimmunology. 2018 Jan 16;7(4)

https://www.ncbi.nlm.nih.gov/pubmed/29632710

 

Rapp C, Warta R, Stamova S, Nowrouzi A, Geisenberger C, Gal Z, Roesch S, Dettling S, Juenger S, Bucur M, Jungk C, DaoTrong P, Ahmadi R, Sahm F, Reuss D, Fermi V, Herpel E, Eckstein V, Grabe N, Schramm C, Weigand MA, Debus J, von Deimling A, Unterberg A, Abdollahi A, Beckhove P, Herold-Mende C.

Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens.

Acta Neuropathol. 2017 Aug;134(2):297-316

https://www.ncbi.nlm.nih.gov/pubmed/28332095

Rathinasamy A, Domschke C, Ge Y, Böhm HH, Dettling S, Jansen D, Lasitschka F, Umansky L, Gräler MH, Hartmann J, Herold-Mende C, Schuetz F, Beckhove P.

Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1.

Cancer Immunol Immunother. 2017 May;66(5):593-603.

https://www.ncbi.nlm.nih.gov/pubmed/28224210

Ochs K, Ott M, Bunse T, Sahm F, Bunse L, Deumelandt K, Sonner JK, Keil M, von Deimling A, Wick W, Platten M. K27M-mutant histone-3 as a novel target for glioma immunotherapy.

Oncoimmunology. 2017 May 12;6(7)

https://www.ncbi.nlm.nih.gov/pubmed/28811969

Wiskemann J., Hummler S., Diepold C., Keil M., Abel U., Steindorf K., Beckhove P., Ulrich C.M., Steins M. and Thomas M.;

POSITIVE study: physical exercise program in non-operable lung cancer patients undergoing palliative treatment.

BMC Cancer. 2016 Jul 16:499 DOI: 10.1186/s12885-016-2561-1

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949758/

Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Holland-Letz, T., Umansky L, Beckhove P, Sucker A, Schadendorf D, Utikal J, Umansky V.

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.

Clin. Cancer Res., 2015, DOI:10.158/1078-0432.CCR-15-0676.

https://www.ncbi.nlm.nih.gov/pubmed/26289067

Schneider T, Sevko A, Heussel CP, Umansky L, Beckhove P, Dienemann H, Safi S, Utikal J, Hoffmann H, Umansky V.

Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small cell lung cancer.

Clin Exp Immunol. 2015, 180:467-474.

https://www.ncbi.nlm.nih.gov/pubmed/25644608

Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P.

Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.

Oncoimmunology. 2015 Mar 16;4(4):1001217. eCollection 2015 Apr.

https://www.ncbi.nlm.nih.gov/pubmed/26137397

Domschke C., Ge Y., Bernahrd I., Schott S., Keim S., Juenger S., Bucur M., Mayer L., Blumenstein M., Rom J., Heil J., Sohn C., Schneeweiss A., Beckhove P., Schetz F.,

Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized brest cancer: follow-up analysis of clinical pilot trial.

Cancer Immunol Immunother. 2013 Jun;62(6):1053-60. Doi: 10.1007/s00262-013-1414-x Epub 2013 Apr 18.

https://www.ncbi.nlm.nih.gov/pubmed/23595207

to top
powered by webEdition CMS